Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.

Bhargava R, Beriwal S, McManus K, Dabbs DJ.

Appl Immunohistochem Mol Morphol. 2011 May;19(3):218-25. doi: 10.1097/PAI.0b013e3181ffc58c.

PMID:
21217522
3.

Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.

Bhargava R, Beriwal S, Striebel JM, Dabbs DJ.

Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):113-8. doi: 10.1097/PAI.0b013e3181b94ff1.

PMID:
19801938
4.

Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.

Singh B, Smith JA, Axelrod DM, Ameri P, Levitt H, Danoff A, Lesser M, de Angelis C, Illa-Bochaca I, Lubitz S, Huberman D, Darvishian F, Kleinberg DL.

Breast Cancer Res. 2014 Nov 11;16(6):463. doi: 10.1186/s13058-014-0463-1.

5.

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.

Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM.

Cancer. 2010 Mar 15;116(6):1431-9. doi: 10.1002/cncr.24876. Erratum in: Cancer. 2011 May 15;117(10):2238.

6.

The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.

Chong YM, Colston K, Jiang WG, Sharma AK, Mokbel K.

Breast Cancer Res Treat. 2006 Oct;99(3):275-88. Epub 2006 Jun 5.

PMID:
16752221
7.
8.

Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.

Heskamp S, Boerman OC, Molkenboer-Kuenen JD, Wauters CA, Strobbe LJ, Mandigers CM, Bult P, Oyen WJ, van der Graaf WT, van Laarhoven HW.

PLoS One. 2015 Feb 13;10(2):e0117745. doi: 10.1371/journal.pone.0117745. eCollection 2015.

9.
10.

EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast.

Vranic S, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LM, Adegboyega P, Hagenkord J, Gatalica Z.

Mod Pathol. 2010 May;23(5):644-53. doi: 10.1038/modpathol.2010.50. Epub 2010 Mar 5.

11.

Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.

Kalinina T, Bockhorn M, Kaifi JT, Thieltges S, Güngör C, Effenberger KE, Strelow A, Reichelt U, Sauter G, Pantel K, Izbicki JR, Yekebas EF.

Int J Cancer. 2010 Oct 15;127(8):1931-40. doi: 10.1002/ijc.25196.

12.

Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma.

Peiró G, Adrover E, Sánchez-Tejada L, Lerma E, Planelles M, Sánchez-Payá J, Aranda FI, Giner D, Gutiérrez-Aviñó FJ.

Mod Pathol. 2011 Feb;24(2):201-8. doi: 10.1038/modpathol.2010.191. Epub 2010 Nov 5.

13.

Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma.

Chen C, Zhou Z, Sheehan CE, Slodkowska E, Sheehan CB, Boguniewicz A, Ross JS.

Int J Cancer. 2009 Jun 15;124(12):2829-36. doi: 10.1002/ijc.24266.

14.

Insulin-like growth factor-1 receptor expression in thymic malignancies.

Girard N, Teruya-Feldstein J, Payabyab EC, Riely GJ, Rusch VW, Kris MG, Zakowski MF.

J Thorac Oncol. 2010 Sep;5(9):1439-46. doi: 10.1097/JTO.0b013e3181e392a8.

15.

Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.

Cabezón T, Gromova I, Gromov P, Serizawa R, Timmermans Wielenga V, Kroman N, Celis JE, Moreira JM.

Mol Cell Proteomics. 2013 Feb;12(2):381-94. doi: 10.1074/mcp.M112.019786. Epub 2012 Nov 20.

17.

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.

Breast Cancer Res Treat. 2012 Feb;131(3):827-36. doi: 10.1007/s10549-011-1488-0. Epub 2011 Apr 7.

PMID:
21472434
18.

Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma.

Kraus JA, Beriwal S, Dabbs DJ, Ahrendt GM, McGuire KP, Johnson RR, Badve P, Puhalla SL, Bhargava R.

Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):334-9. doi: 10.1097/PAI.0b013e31823f4663.

PMID:
22417856
19.

High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.

Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF, Lee AV.

Clin Cancer Res. 2011 Apr 15;17(8):2314-27. doi: 10.1158/1078-0432.CCR-10-1903. Epub 2010 Dec 22.

20.

Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.

Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J, van de Water B.

Breast Cancer Res. 2011 May 19;13(3):R52. doi: 10.1186/bcr2883.

Supplemental Content

Support Center